Health
‘Another agent in our arsenal’: Finerenone benefits extend to those with, without CVD – Healio
Among adults with chronic kidney disease and type 2 diabetes, the mineralocorticoid receptor inhibitor antagonist finerenone reduced the incidence of CV events…
Source/Disclosures
Source: Filippatos G, et al. LBS.07: Randomized trials — brain, kidney and heart. Presented at: American Heart Association Scientific Sessions; Nov. 13-17, 2020 (virtual meeting).
Disclosures:
Filippatos reports he receives lecture or advisory board fees from Amgen, Bayer, Boehringer Ingelheim, Medtronic, Novartis, Servier and Vifor. Wanner reports he receives lecture or advisory fees from AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, FMC, Gilead, GlaxoSmithKline and…
-
Noosa News22 hours agoMan dies after stabbing in inner-city unit
-
General11 hours agoCoalition abandons ‘end’ to work from home, walks back 41,000 job cuts
-
Noosa News23 hours agoAgriculture department confirms US beef not banned in Australia
-
General17 hours agoSector warns Coalition’s plan to limit overseas students ‘straight out of Trump’s playbook’